Effects of low-dose TRH on cognitive deficits in the ECT postictal state.
A low dose (0.5 mg) of thyrotropin-releasing hormone (TRH), a short-acting tripeptide with known analeptic properties, was administered to eight depressed patients 5 minutes after ECT session 3 or 4 in a double-blind, placebo-controlled crossover design. After TRH infusion the patients displayed selectively better performance on a battery of neuropsychological tests than they did after placebo infusion. Further exploration with pharmacological probes to mitigate ECT postictal cognitive deficits is warranted.
Khan
A
A
Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle 98195.
Mirolo
M H
MH
Claypoole
K
K
Bhang
J
J
Cox
G
G
Horita
A
A
Tucker
G
G
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D003072:Cognition Disorders / Q000209:etiology / Q000517:prevention & control*; D018592:Cross-Over Studies; D003866:Depressive Disorder / Q000628:therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004565:Electroconvulsive Therapy / Q000009:adverse effects; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010919:Placebos; D013973:Thyrotropin-Releasing Hormone / Q000008:administration & dosage* / Q000627:therapeutic use
D010919:Placebos; D013973:Thyrotropin-Releasing Hormone